Skip to main content

Vestal Point Capital, LP

13F filer · CIK 0001974915
Reported Aug 14, 2026
Net seller this quarter
13F portfolio value$4.28BU.S. long equity reported on 13F
Positions689 new · 31 closed
Net flow last quarter-$57.8MBuys minus sells
Top 10 positions weight50.3%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Aug 14, 202668 positions
BMRNBiomarin Pharmaceutical Inc$345M8.06%3.11%+68.5%Q1 2024
NBIXNeurocrine Biosciences Inc$317M7.40%1.85%+50.4%Q4 2023
ABVXAbivax S.A.$313M7.32%2.99%+56.6%Q3 2025
UTHRUNITED THERAPEUTICS Corp$236M5.51%1.02%+480.0%Q1 2026
ELVNEnliven Therapeutics, Inc.$203M4.74%5.46%+23.1%Q2 2025
NRIXNurix Therapeutics, Inc.$195M4.56%7.76%+23.9%Q2 2024
BCAXBicara Therapeutics Inc.$156M3.64%7.96%-3.2%Q3 2024
TSHATaysha Gene Therapies, Inc.$132M3.09%5.97%+7.9%Q2 2025
ARWRArrowhead Pharmaceuticals, Inc.$128M3.00%1.12%-30.8%Q4 2025
ABTAbbott Laboratories$127M2.97%0.08%Not reportedQ2 2025
ZBHZimmer Biomet Holdings, Inc.$121M2.82%0.72%+636.8%Q2 2025
IRONDisc Medicine, Inc.$113M2.65%4.04%+121.4%Q2 2025
GLUEMonte Rosa Therapeutics, Inc.$111M2.60%5.40%+27.7%Q2 2024
PODDInsulet Corp$102M2.38%0.97%+1224.1%Q1 2026
ASNDAscendis Pharma A/S$100M2.34%0.61%Not reportedQ4 2023
AZNAstrazeneca PLC$85.3M1.99%Not reported+350.0%Q4 2023
SNYSanofi$85.3M1.99%0.16%+42.9%Q4 2023
RVMDRevolution Medicines, Inc.$84.3M1.97%0.21%-81.1%Q4 2023
BCRXBiocryst Pharmaceuticals Inc$83M1.94%3.25%+18.2%Q4 2025
DYNDyne Therapeutics, Inc.$75M1.75%2.04%-15.6%Q2 2024
NKTRNektar Therapeutics$69.8M1.63%4.91%+250.9%Q1 2026
GMEDGlobus Medical Inc$67.2M1.57%0.63%+39.2%Q4 2023
TARSTarsus Pharmaceuticals, Inc.$66.1M1.54%2.43%+425.0%Q3 2024
IMTXImmatics N.V.$62.6M1.46%4.61%Not reportedQ4 2023
TRVITrevi Therapeutics, Inc.$57.8M1.35%2.18%+43.1%Q1 2026
IMCRImmunocore Holdings plc$57.2M1.34%3.50%-34.9%Q4 2025
RGENRepligen Corp$54.6M1.28%0.71%-56.8%Q3 2025
BMYBristol Myers Squibb Co$46.1M1.08%0.04%-20.0%Q2 2024
QUREuniQure N.V.$43.1M1.01%1.35%+160.5%Q4 2023
XENEXenon Pharmaceuticals Inc.$42.3M0.99%0.72%+9.4%Q4 2023
DRUGBright Minds Biosciences Inc.$38.3M0.89%7.14%+10.7%Q1 2026
MDGLMadrigal Pharmaceuticals, Inc.$34.9M0.82%0.28%+106.6%Q3 2024
ALCAlcon Inc$33.6M0.78%0.10%-37.5%Q2 2025
MYGNMyriad Genetics Inc$32.7M0.77%6.00%+248.0%Q3 2025
RAPPRapport Therapeutics, Inc.$30.4M0.71%1.52%-49.2%Q3 2025
CBIOCrescent Biopharma, Inc.$29.3M0.69%5.87%+8.7%Q4 2025
GEHCGE HealthCare Technologies Inc.$28.8M0.67%0.10%+80.0%Q1 2025
INSMINSMED Inc$26.7M0.62%0.11%Not reportedQ4 2023
VKTXViking Therapeutics, Inc.$26.5M0.62%0.58%-25.6%Q1 2024
BBNXBeta Bionics, Inc.$25.1M0.59%3.56%-27.7%Q2 2025
REGNRegeneron Pharmaceuticals, Inc.$24.9M0.58%0.04%Not reportedQ4 2023
SLDBSolid Biosciences Inc.$21.6M0.50%2.05%-56.8%Q4 2023
ANROAlto Neuroscience, Inc.$20.7M0.48%2.24%-62.0%Q1 2024
TRAXFirst Tracks Biotherapeutics, Inc.$20.4M0.48%2.86%NewQ2 2026
LXEOLexeo Therapeutics, Inc.$20.1M0.47%5.49%-3.5%Q1 2024
SVRASavara Inc$16.8M0.39%1.32%+4.6%Q2 2024
DMRADamora Therapeutics, Inc.$15M0.35%0.93%-4.2%Q1 2026
SGPSpyGlass Pharma, Inc.$14.9M0.35%2.00%+0.5%Q1 2026
TECXTectonic Therapeutic, Inc.$14.6M0.34%2.21%+29.6%Q4 2025
AVTXAvalo Therapeutics, Inc.$14.3M0.33%1.47%NewQ2 2026
Q1 2026Reported May 15, 202690 positions
RVMDRevolution Medicines, Inc.$231M6.46%1.19%+705.1%Q4 2023
BMRNBiomarin Pharmaceutical Inc$202M5.65%1.85%+19.2%Q1 2024
ABVXAbivax S.A.$167M4.67%1.91%-21.1%Q3 2025
NBIXNeurocrine Biosciences Inc$165M4.60%1.24%Not reportedQ4 2023
ARWRArrowhead Pharmaceuticals, Inc.$143M3.99%1.62%+152.8%Q4 2025
ELVNEnliven Therapeutics, Inc.$127M3.56%5.34%-15.1%Q2 2025
RGENRepligen Corp$109M3.05%1.64%+1014.5%Q3 2025
BCAXBicara Therapeutics Inc.$108M3.02%8.28%+51.8%Q3 2024
NRIXNurix Therapeutics, Inc.$101M2.82%6.29%+38.6%Q2 2024
APGEApogee Therapeutics, Inc.$92.6M2.59%1.47%+100.0%Q3 2024
ASNDAscendis Pharma A/S$85.8M2.40%0.61%+114.3%Q4 2023
IMCRImmunocore Holdings plc$83.4M2.33%5.44%+373.0%Q4 2025
TSHATaysha Gene Therapies, Inc.$80.5M2.25%6.27%+30.9%Q2 2025
DYNDyne Therapeutics, Inc.$72.5M2.03%2.42%+3233.3%Q2 2024
SNYSanofi$67.5M1.89%0.11%Not reportedQ4 2023
BCRXBiocryst Pharmaceuticals Inc$66.9M1.87%2.77%+212.2%Q4 2025
SRRKScholar Rock Holding Corp$65.1M1.82%1.11%+89.2%Q1 2025
IMTXImmatics N.V.$60.8M1.70%4.61%+0.8%Q4 2023
BMYBristol Myers Squibb Co$60.7M1.70%0.05%+300.0%Q2 2024
ALCAlcon Inc$60.3M1.69%0.16%-27.6%Q2 2025
GLUEMonte Rosa Therapeutics, Inc.$59.3M1.66%4.27%+365.0%Q2 2024
VERAVera Therapeutics, Inc.$55M1.54%2.14%+148.8%Q4 2024
TERNTerns Pharmaceuticals, Inc.$52.7M1.47%0.87%-77.8%Q4 2025
GMEDGlobus Medical Inc$52.6M1.47%0.45%-52.1%Q4 2023
BSXBoston Scientific Corp$50.2M1.40%0.05%NewQ1 2026
NUVLNuvalent, Inc.$49.4M1.38%15.39%+947.2%Q4 2023
COGTCogent Biosciences, Inc.$47.4M1.32%0.72%Not reportedQ1 2025
ANROAlto Neuroscience, Inc.$46.4M1.30%5.89%-16.9%Q1 2024
RAPPRapport Therapeutics, Inc.$44.9M1.26%3.00%+29.4%Q3 2025
IRONDisc Medicine, Inc.$44.8M1.25%1.83%-4.8%Q2 2025
UTHRUNITED THERAPEUTICS Corp$44.5M1.24%0.18%NewQ1 2026
CLDXCelldex Therapeutics, Inc.$38.8M1.09%1.84%+5.1%Q4 2024
KALVKalVista Pharmaceuticals, Inc.$37.2M1.04%3.61%-2.1%Q1 2024
XENEXenon Pharmaceuticals Inc.$37.2M1.04%0.66%+6.7%Q4 2023
SLDBSolid Biosciences Inc.$36M1.01%5.08%-14.0%Q4 2023
DRUGBright Minds Biosciences Inc.$35.9M1.00%6.45%NewQ1 2026
PTGXProtagonist Therapeutics, Inc$34.4M0.96%0.51%NewQ1 2026
DNLIDenali Therapeutics Inc.$34M0.95%1.12%+281.4%Q2 2024
REGNRegeneron Pharmaceuticals, Inc.$30.9M0.86%0.04%Not reportedQ4 2023
WATWaters Corp$29.8M0.83%0.10%NewQ1 2026
VKTXViking Therapeutics, Inc.$29.7M0.83%0.79%Not reportedQ1 2024
INSPInspire Medical Systems, Inc.$27.8M0.78%1.87%Not reportedQ2 2024
CBIOCrescent Biopharma, Inc.$27.6M0.77%5.44%Not reportedQ4 2025
TRVITrevi Therapeutics, Inc.$25.8M0.72%1.69%NewQ1 2026
LXEOLexeo Therapeutics, Inc.$25.7M0.72%6.04%Not reportedQ1 2024
SLNOSoleno Therapeutics Inc$24.4M0.68%1.41%Not reportedQ4 2023
BBNXBeta Bionics, Inc.$22.2M0.62%4.96%+268.6%Q2 2025
NKTRNektar Therapeutics$20.5M0.57%1.40%NewQ1 2026
CYTKCytokinetics Inc$19.8M0.55%0.24%Not reportedQ4 2023
AZNAstrazeneca PLC$19.7M0.55%Not reportedNot reportedQ4 2023
Q4 2025Reported Feb 17, 202675 positions
ABVXAbivax S.A.$256M8.71%2.42%+90.0%Q3 2025
ACLXArcellx, Inc.$191M6.48%5.05%+134.0%Q4 2023
TERNTerns Pharmaceuticals, Inc.$182M6.18%4.01%NewQ4 2025
BMRNBiomarin Pharmaceutical Inc$178M6.06%1.56%+261.5%Q1 2024
GMEDGlobus Medical Inc$111M3.78%0.95%+2.0%Q4 2023
NRIXNurix Therapeutics, Inc.$89M3.02%4.61%+35.0%Q2 2024
ALCAlcon Inc$87.1M2.96%0.23%+0.5%Q2 2025
DXCMDexcom Inc$84.6M2.88%0.33%+96.2%Q3 2025
MRKMerck & Co., Inc.$81.6M2.77%0.03%Not reportedQ4 2023
TSHATaysha Gene Therapies, Inc.$75.6M2.57%4.82%+150.0%Q2 2025
ABTAbbott Laboratories$75.2M2.56%0.03%+140.0%Q2 2025
IMTXImmatics N.V.$64.3M2.19%4.57%-3.5%Q4 2023
TYRATyra Biosciences, Inc.$63.8M2.17%4.52%Not reportedQ4 2024
BCAXBicara Therapeutics Inc.$60.2M2.05%6.32%-29.9%Q3 2024
ARWRArrowhead Pharmaceuticals, Inc.$59.8M2.03%0.66%NewQ4 2025
ELVNEnliven Therapeutics, Inc.$59M2.01%6.44%+230.2%Q2 2025
IRONDisc Medicine, Inc.$58.4M1.98%1.94%+47.0%Q2 2025
JAZZJazz Pharmaceuticals plc$49.3M1.68%0.47%-42.0%Q4 2023
DAWNDay One Biopharmaceuticals, Inc.$48.5M1.65%5.05%+94.4%Q2 2024
LXEOLexeo Therapeutics, Inc.$44.4M1.51%6.13%+37.7%Q1 2024
ANROAlto Neuroscience, Inc.$44.2M1.50%7.78%+161.6%Q1 2024
APGEApogee Therapeutics, Inc.$41.5M1.41%0.80%+29.4%Q3 2024
OLMAOlema Pharmaceuticals, Inc.$41.3M1.40%2.03%NewQ4 2025
AXSMAxsome Therapeutics, Inc.$38.4M1.30%0.41%+40.0%Q2 2024
ASNDAscendis Pharma A/S$37.3M1.27%0.28%-70.8%Q4 2023
RAPPRapport Therapeutics, Inc.$33.7M1.14%2.32%+16.8%Q3 2025
SLDBSolid Biosciences Inc.$32.8M1.12%7.36%+95.5%Q4 2023
CLDXCelldex Therapeutics, Inc.$31.6M1.08%1.75%-3.3%Q4 2024
SRRKScholar Rock Holding Corp$30.8M1.05%0.65%-53.3%Q1 2025
KALVKalVista Pharmaceuticals, Inc.$30.5M1.04%3.71%+152.0%Q1 2024
VERAVera Therapeutics, Inc.$27.9M0.95%0.86%-27.6%Q4 2024
XENEXenon Pharmaceuticals Inc.$26.9M0.91%0.75%-45.5%Q4 2023
LNTHLantheus Holdings, Inc.$24M0.81%0.56%+111.8%Q2 2025
RVMDRevolution Medicines, Inc.$23.5M0.80%0.15%-53.2%Q4 2023
ZYMEZymeworks Inc.$22.8M0.77%1.16%-51.0%Q2 2024
IMCRImmunocore Holdings plc$20.3M0.69%1.15%NewQ4 2025
UPBUpstream Bio, Inc.$19.5M0.66%1.33%NewQ4 2025
BBNXBeta Bionics, Inc.$18.3M0.62%1.35%Not reportedQ2 2025
CBIOCrescent Biopharma, Inc.$17.8M0.60%5.44%NewQ4 2025
BCRXBiocryst Pharmaceuticals Inc$17.6M0.60%1.06%NewQ4 2025
PENPenumbra Inc$15.5M0.53%0.13%Not reportedQ3 2024
GERNGeron Corp$14.9M0.51%1.77%-34.3%Q1 2024
RGENRepligen Corp$13.6M0.46%0.15%-79.3%Q3 2025
ZBHZimmer Biomet Holdings, Inc.$13.5M0.46%0.08%Not reportedQ2 2025
BMYBristol Myers Squibb Co$13.5M0.46%0.01%Not reportedQ2 2024
GLUEMonte Rosa Therapeutics, Inc.$12.2M0.41%1.18%-3.1%Q2 2024
FULCFulcrum Therapeutics, Inc.$10.7M0.37%1.43%Not reportedQ4 2023
SVRASavara Inc$9.68M0.33%0.79%-60.0%Q2 2024
ENGNenGene Therapeutics Inc.$9.53M0.32%1.58%+185.1%Q4 2024
AGIOAgios Pharmaceuticals, Inc.$8.85M0.30%0.56%+155.9%Q1 2024
Q3 2025Reported Nov 14, 202580 positions
ASNDAscendis Pharma A/S$119M5.39%0.99%+200.0%Q4 2023
ACLXArcellx, Inc.$103M4.63%2.16%-54.6%Q4 2023
NUVLNuvalent, Inc.$95.1M4.30%35.15%+2.3%Q4 2023
ABVXAbivax S.A.$84.9M3.83%1.58%NewQ3 2025
ALCAlcon Inc$82M3.70%0.22%+109.5%Q2 2025
BCAXBicara Therapeutics Inc.$80.5M3.64%9.34%+2.0%Q3 2024
FOLDAmicus Therapeutics, Inc.$76.8M3.47%3.16%-18.1%Q4 2024
GMEDGlobus Medical Inc$71.6M3.23%0.93%+150.0%Q4 2023
IONSIonis Pharmaceuticals Inc$70.3M3.18%0.67%+115.0%Q4 2024
JAZZJazz Pharmaceuticals plc$65.9M2.98%0.82%-58.3%Q4 2023
BDXBecton Dickinson & Co$60.8M2.75%0.11%+1200.0%Q3 2024
SRRKScholar Rock Holding Corp$55.9M2.52%1.51%Not reportedQ1 2025
IMTXImmatics N.V.$54.1M2.44%5.22%+1.6%Q4 2023
RGENRepligen Corp$53.5M2.41%0.71%NewQ3 2025
DNTHDianthus Therapeutics, Inc.$46.4M2.10%2.75%-63.1%Q4 2023
BMRNBiomarin Pharmaceutical Inc$45M2.03%0.43%+66.0%Q1 2024
XENEXenon Pharmaceuticals Inc.$44.2M1.99%1.43%-45.0%Q4 2023
DXCMDexcom Inc$43.7M1.98%0.17%NewQ3 2025
CYTKCytokinetics Inc$39.8M1.80%0.61%-75.6%Q4 2023
BIIBBiogen Inc.$38.5M1.74%0.19%Not reportedQ4 2023
CDTXCidara Therapeutics, Inc.$38.3M1.73%1.36%-20.0%Q1 2025
ATXSAstria Therapeutics, Inc.$36.1M1.63%8.78%+9.6%Q1 2024
DYNDyne Therapeutics, Inc.$35.1M1.59%1.95%+281.4%Q2 2024
TYRATyra Biosciences, Inc.$33.9M1.53%4.55%-8.7%Q4 2024
ABTAbbott Laboratories$33.5M1.51%0.01%+42.9%Q2 2025
IRONDisc Medicine, Inc.$33M1.49%1.43%+257.1%Q2 2025
NRIXNurix Therapeutics, Inc.$32.1M1.45%4.52%+73.8%Q2 2024
CRNXCrinetics Pharmaceuticals, Inc.$31.2M1.41%0.79%-50.0%Q4 2023
CLDXCelldex Therapeutics, Inc.$31.2M1.41%1.81%-31.1%Q4 2024
ZYMEZymeworks Inc.$30.1M1.36%2.35%+53.5%Q2 2024
DHRDanaher Corp$29.7M1.34%0.02%+200.0%Q1 2025
RVMDRevolution Medicines, Inc.$29.4M1.33%0.33%-47.5%Q4 2023
RAPPRapport Therapeutics, Inc.$28.2M1.27%1.99%NewQ3 2025
ELVNEnliven Therapeutics, Inc.$23.7M1.07%1.96%+364.0%Q2 2025
GERNGeron Corp$23.6M1.07%2.70%-27.6%Q1 2024
BLTEBelite Bio, Inc$23.1M1.04%0.98%NewQ3 2025
RAREUltragenyx Pharmaceutical Inc.$22.6M1.02%0.78%Not reportedQ1 2024
VERAVera Therapeutics, Inc.$22.1M1.00%1.19%-75.5%Q4 2024
LXEOLexeo Therapeutics, Inc.$21.6M0.97%5.92%+0.7%Q1 2024
BDTXBlack Diamond Therapeutics, Inc.$21M0.95%9.75%-0.9%Q2 2024
DAWNDay One Biopharmaceuticals, Inc.$18.9M0.85%2.61%-10.8%Q2 2024
SLDBSolid Biosciences Inc.$18.4M0.83%3.82%+97.7%Q4 2023
AXSMAxsome Therapeutics, Inc.$18.2M0.82%0.30%Not reportedQ2 2024
TSHATaysha Gene Therapies, Inc.$18M0.81%2.01%+83.3%Q2 2025
APGEApogee Therapeutics, Inc.$16.9M0.76%0.72%Not reportedQ3 2024
SVRASavara Inc$14.3M0.65%2.32%-63.6%Q2 2024
BRKRBruker Corp$14.3M0.65%0.29%-12.0%Q3 2024
REGNRegeneron Pharmaceuticals, Inc.$14.1M0.63%0.03%Not reportedQ4 2023
QUREuniQure N.V.$13.1M0.59%0.36%-93.9%Q4 2023
BBNXBeta Bionics, Inc.$11.9M0.54%1.36%+9.1%Q2 2025
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.